Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06101134 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT06101134 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06101134, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.

Conditions Studied

Melanoma

Interventions

  • DRUG relatlimab+nivolumab
  • DRUG nivolumab
  • DRUG relatlimab+nivolumab+rHuPH20
  • DRUG nivolumab+rHuPH20

Study Locations (20)

Other

  • Local Institution - 0005 - Concepción
  • Local Institution - 0023 - Holargos, Athens
  • Local Institution - 0008 - Piraeus
  • Local Institution - 0033 - Thessaloniki

Washington

  • Local Institution - 0037 - Edmonds
  • Local Institution - 0036 - Issaquah
  • Local Institution - 0030 - Seattle

I

  • Local Institution - 0014 - Athens
  • Local Institution - 0029 - Marousi

Alaska

  • Local Institution - 0007 - Anchorage

Arizona

  • Local Institution - 0013 - Phoenix

California

  • Local Institution - 0010 - San Francisco

Georgia

  • Local Institution - 0034 - Atlanta

Kentucky

  • Local Institution - 0032 - Edgewood

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-11-06
Est. Completion 2027-08-31
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06101134

The ClinicalTrials.gov registry entry for NCT06101134 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which relatlimab+nivolumab is the first listed.

NCT06101134 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Washington, I.

Frequently Asked Questions

What is clinical trial NCT06101134 about?

NCT06101134 is a clinical study titled "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations". The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safe...

What is the current status of trial NCT06101134?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-11-06. Estimated completion is 2027-08-31.

What conditions does trial NCT06101134 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT06101134?

The interventions under investigation include: relatlimab+nivolumab (DRUG), nivolumab (DRUG), relatlimab+nivolumab+rHuPH20 (DRUG), nivolumab+rHuPH20 (DRUG).

Who is sponsoring clinical trial NCT06101134?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06101134 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.